GLP-1 Dosing Mistakes 2026: Why Poison Control Calls Nearly Doubled

A study published in the Journal of Medical Toxicology — the official journal of the American College of Medical Toxicology — found that U.S. poison control centers logged a dramatic surge in calls related to GLP-1 receptor agonists after semaglutide's FDA approval for weight management, and that most of those calls trace back to two simple, preventable dosing mistakes (Miller, Miller, Varney, Han, 2026, Journal of Medical Toxicology, DOI 10.1007/s13181-026-01121-z). This isn't a story about drug danger in the abstract — it's a story about patient education gaps that are costing thousands of people unnecessary trips to the emergency room.

The Data: How Big Is This Surge, Really?

Before and After FDA Approval

Prior to 2021, U.S. poison control centers nationally handled roughly 1,000 to 1,500 GLP-1-related cases per year — a relatively low, stable baseline. After the FDA's mid-2021 approval of semaglutide for weight management, that volume nearly doubled, and by 2023 poison centers had logged more than 8,000 GLP-1-related calls in a single year (ScienceDaily coverage of Miller et al., Journal of Medical Toxicology).

Semaglutide Dominates the Case Volume

A related analysis led by the same University of Texas at San Antonio research team found semaglutide accounted for 64% of all GLP-1-related poison control calls — a proportion one researcher called "staggering," though she noted it aligns with the drug's outsized media attention and market share relative to other GLP-1 products (HealthDay coverage).

Severity Is Trending Up, Too

The proportion of poison control cases resulting in referral to a healthcare facility increased from 23% to 33.5% over the study period — meaning not only are calls increasing in volume, but a growing share require actual medical evaluation rather than being resolved with phone guidance alone.

The Two Mistakes Driving Most Cases

Mistake #1: Daily Dosing Instead of Weekly

Semaglutide is designed to be injected once per week — its long half-life (roughly one week) is precisely why once-weekly dosing works pharmacologically. Patients who mistakenly inject daily are effectively giving themselves a massive cumulative overdose within days, since the drug hasn't cleared from a prior dose before the next one arrives.

Mistake #2: Starting at the Highest Dose Immediately

GLP-1 medications use a gradual titration schedule specifically to let the body adjust and to minimize gastrointestinal side effects. Patients who start at the highest available dose — skipping the step-by-step schedule entirely — face a significantly elevated risk of severe nausea, vomiting, and other adverse effects that prompt poison control calls. See our dose escalation guide for what the correct titration schedule actually looks like.

Why These Mistakes Happen

Researchers point to gaps in patient education at every step of the process — from the doctor's office, to the pharmacy counter, to at-home self-administration — as the core preventable factor. Many of these errors are not the result of patient carelessness so much as insufficient plain-language instruction at the point of prescribing or dispensing.

Compounded Products Add a Distinct Risk Layer

Separate from the daily-vs-weekly and titration mistakes, compounded semaglutide products carry their own documented risk pattern tied to how they're packaged and dosed:

The Vial-and-Syringe Problem

Unlike FDA-approved semaglutide pens, which come pre-measured, compounded semaglutide is often dispensed in multi-dose vials requiring patients to draw up their own dose with a syringe — introducing multiple points of potential error (FDA alert on compounded semaglutide dosing errors).

Unit Confusion: mg vs. mL vs. "Units"

The FDA has documented cases where patients were instructed to draw a specific number of "units" from a vial using an insulin syringe, but mistakenly administered 10 times the intended amount — for example, drawing 50 units instead of the intended 5. In several cases, prescribers themselves made the conversion error, prescribing 25 units instead of an intended 5-unit (0.25 mg) dose, resulting in a fivefold overdose.

Reported Overdose Range

The FDA has received reports of patients administering five to 20 times their intended dose of compounded semaglutide due to these vial-and-syringe conversion issues, with adverse events including severe nausea, vomiting, abdominal pain, dehydration, and in some cases acute pancreatitis or gallstones requiring hospitalization (FDA compounding alert).

See our compounded GLP-1 guide for a fuller comparison of compounded versus brand-name products and the FDA's current regulatory posture toward compounding.

What Poison Control Calls Actually Look Like

Typical Symptoms Reported

Most cases involve gastrointestinal effects — nausea, vomiting, abdominal pain — consistent with an acute overdose of a medication whose most common side effects are GI-related at any dose, let alone a multiplied one.

When It Becomes More Serious

Reported severe outcomes include fainting, dehydration requiring IV fluids, acute pancreatitis, and gallstones. Most patients recover with supportive care (antiemetics, IV fluids), but the growing share of cases requiring facility-level evaluation signals these aren't universally minor events.

What Patients and Caregivers Should Actually Do

If You're Starting a GLP-1 for the First Time

• Confirm directly with your prescriber and pharmacist: is this a once-weekly or once-daily medication? Say the frequency back to them to confirm you heard it correctly.
• Ask to see the titration schedule in writing — don't rely on memory for a dosing plan that spans weeks or months.
• If using a vial-and-syringe compounded product, ask your pharmacist to physically demonstrate the correct draw volume before you leave, and confirm whether your dose is measured in mg, mL, or units.

If You Suspect a Dosing Error Has Already Happened

Contact Poison Control (1-800-222-1222 in the U.S.) or seek medical attention immediately, particularly if you've experienced severe vomiting, fainting, or signs of dehydration. Don't wait to see if symptoms resolve on their own if you know you've taken significantly more than intended.

For Caregivers of Older Adults

Given that dosing confusion disproportionately affects patients unfamiliar with self-injection, caregivers assisting older relatives with GLP-1 administration should independently verify the weekly-versus-daily schedule and the current titration step rather than assuming the patient has it memorized correctly.

Why This Matters as GLP-1 Use Keeps Climbing

With roughly 11% of U.S. adults now using GLP-1 medications for weight loss — up from 3% in 2024 — and continued expansion through programs like the new Medicare GLP-1 Bridge, the population at risk for these preventable dosing errors is only growing. Researchers frame this less as a reason for alarm and more as a clear, addressable education gap: better instruction at the prescribing and dispensing level could meaningfully reduce a documented, measurable harm pattern.

The Bigger Picture: Education Gaps, Not Drug Danger

It's worth being precise about what this research does and doesn't say. The study is not evidence that GLP-1 medications are inherently unsafe when used as directed — it's evidence that a specific, identifiable set of instructions isn't reliably reaching patients before they self-administer these drugs at home. That distinction matters for how the healthcare system should respond: the fix researchers point to is better plain-language education at the point of prescribing and dispensing, not new restrictions on the medications themselves.

This pattern echoes something seen with other self-injected medications historically, including insulin, where unit-based dosing and pen-versus-vial confusion has long been a documented source of preventable errors. The GLP-1 surge is, in some sense, a scaled-up repeat of a known patient-safety challenge — just arriving faster and at greater volume because of how quickly these drugs have been adopted. Pharmacists and prescribers who have experience with insulin counseling are increasingly being asked to apply those same teaching techniques to GLP-1 patients, and early anecdotal reports suggest structured teach-back counseling (having the patient repeat the schedule back before leaving the pharmacy) meaningfully reduces confusion.

Educational content only. Not medical advice. If you suspect a medication overdose or dosing error, contact Poison Control (1-800-222-1222) or seek emergency medical care immediately.

Frequently Asked Questions

Why have GLP-1 poison control calls increased so much?

Poison control calls involving GLP-1 drugs nearly doubled after semaglutide's 2021 FDA approval for weight management and topped 8,000 cases annually by 2023, driven primarily by patients taking the medication daily instead of weekly or starting at the highest dose instead of titrating gradually.

What are the most common GLP-1 dosing mistakes?

The two most frequently reported errors are injecting semaglutide daily instead of the intended once-weekly schedule, and starting treatment at the highest available dose rather than following the step-by-step titration schedule.

Is compounded semaglutide riskier for dosing errors than brand-name pens?

Compounded semaglutide dispensed in multi-dose vials carries a documented, distinct risk because patients must draw their own dose with a syringe, creating opportunities for mg/mL/unit conversion errors that FDA-approved pre-measured pens are designed to eliminate.

What should I do if I think I took too much of my GLP-1 medication?

Contact Poison Control at 1-800-222-1222 or seek medical attention immediately, especially if you're experiencing severe vomiting, fainting, or dehydration symptoms.

Are most GLP-1 poison control cases intentional misuse?

No. Researchers found the substantial majority of cases resulted from unintentional dosing or therapeutic errors, not deliberate misuse.

Which GLP-1 drug is most associated with poison control calls?

Semaglutide accounted for 64% of all GLP-1-related poison control calls in the research team's analysis, which researchers attributed partly to its outsized media attention and broad use.

Sources

1. Miller J, Miller R, Varney SM, Han D. National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss. *Journal of Medical Toxicology*, 2026;22(2):275. DOI: 10.1007/s13181-026-01121-z10.1007/s13181-026-01121-z
2. FDA — FDA Alerts Health Care Providers, Compounders, and Patients of Dosing Errors Associated With Compounded Semaglutide: fda.govfda.gov
3. HealthDay — GLP-1 Weight-Loss Boom Linked to Surge in Poison Control Calls: healthday.com (June 25, 2026)healthday.com